WO1999026902A1 - Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide - Google Patents
Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide Download PDFInfo
- Publication number
- WO1999026902A1 WO1999026902A1 PCT/GB1998/003523 GB9803523W WO9926902A1 WO 1999026902 A1 WO1999026902 A1 WO 1999026902A1 GB 9803523 W GB9803523 W GB 9803523W WO 9926902 A1 WO9926902 A1 WO 9926902A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- linker
- resin
- compounds
- scheme
- general formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000007790 solid phase Substances 0.000 title claims description 22
- 238000005516 engineering process Methods 0.000 title description 4
- 238000004873 anchoring Methods 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 125000000524 functional group Chemical group 0.000 claims abstract description 10
- 239000002243 precursor Substances 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- -1 linker compounds Chemical class 0.000 claims abstract description 8
- 125000006239 protecting group Chemical group 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 48
- 229920005989 resin Polymers 0.000 claims description 45
- 239000011347 resin Substances 0.000 claims description 45
- 125000005647 linker group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000000543 intermediate Substances 0.000 claims description 15
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000816 peptidomimetic Chemical group 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 238000006243 chemical reaction Methods 0.000 abstract description 16
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- 238000013459 approach Methods 0.000 abstract description 7
- 238000005859 coupling reaction Methods 0.000 abstract description 7
- 230000008878 coupling Effects 0.000 abstract description 6
- 238000010168 coupling process Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract description 3
- 125000001033 ether group Chemical group 0.000 abstract description 3
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 229910001868 water Inorganic materials 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 0 *c(c(O*)c1)cc(C=O)c1O Chemical compound *c(c(O*)c1)cc(C=O)c1O 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- AJNODGOFPDCCEV-UHFFFAOYSA-N C(C)(C)(C)OC=1C=CC(=C(C1)O)SSC1=C(C(=CC=C1)OC(C)(C)C)O Chemical compound C(C)(C)(C)OC=1C=CC(=C(C1)O)SSC1=C(C(=CC=C1)OC(C)(C)C)O AJNODGOFPDCCEV-UHFFFAOYSA-N 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229920003180 amino resin Polymers 0.000 description 2
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- MGMWQSVSOGNGPL-UHFFFAOYSA-N methyl 2-bromopentanoate Chemical compound CCCC(Br)C(=O)OC MGMWQSVSOGNGPL-UHFFFAOYSA-N 0.000 description 2
- 229940032007 methylethyl ketone Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 125000003156 secondary amide group Chemical group 0.000 description 2
- 150000003334 secondary amides Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- ASRSBXRMOCLKQC-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)-n-methoxyacetamide Chemical group CONC(=O)COC1=CC=C(Cl)C=C1C ASRSBXRMOCLKQC-UHFFFAOYSA-N 0.000 description 1
- ZNJRONVKWRHYBF-UHFFFAOYSA-N 2-[2-[2-(1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-yl)ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound O1C(C)=CC(=C(C#N)C#N)C=C1C=CC1=CC(CCCN2CCC3)=C2C3=C1 ZNJRONVKWRHYBF-UHFFFAOYSA-N 0.000 description 1
- FHCPJYGXEDXKFM-UHFFFAOYSA-N 2-methoxy-1-[[2-methoxy-4-[(2-methylpropan-2-yl)oxy]phenyl]disulfanyl]-4-[(2-methylpropan-2-yl)oxy]benzene Chemical compound COC1=CC(OC(C)(C)C)=CC=C1SSC1=CC=C(OC(C)(C)C)C=C1OC FHCPJYGXEDXKFM-UHFFFAOYSA-N 0.000 description 1
- VKQQIXXIVRYERY-UHFFFAOYSA-N 5-(5-formyl-4-hydroxy-2-methoxyphenyl)sulfanylpentanoic acid Chemical compound COC1=CC(O)=C(C=O)C=C1SCCCCC(O)=O VKQQIXXIVRYERY-UHFFFAOYSA-N 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- RAVVJKCSZXAIQP-UHFFFAOYSA-N methyl 5-bromopentanoate Chemical compound COC(=O)CCCCBr RAVVJKCSZXAIQP-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003511 tertiary amides Chemical class 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/74—Unsaturated compounds containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- Combinatorial chemistry techniques which are methods for the parallel preparation of many molecules compared to traditional single serial techniques, have the potential to play a pivotal role in the design and development of drug-like molecules.
- International Application No. WO 97/40065 describes a combinatorial library technology which has been developed as a tool to accelerate the development of inhibitors of proteolytic enzymes.
- a protease is screened against a large addressable library of potential protease substrates, swiftly providing an assay for proteolytic activity based upon internally quenched fluorescence.
- a wealth of substrate structure-activity data is gathered which may be used in the design of an inhibitor.
- International Application No. WO 98/17628 describes a novel solid-phase methodology allowing flexible variation of the N and C termini of a discrete target compound, or a combinatorial approach leading to parallel preparation of many analogues of a target compound. This approach allows for great flexibility in the primary sequence assembly of many chemical classes of compound libraries.
- a potential limitation to International Application No. WO 98/17628 may be encountered when considering a further level of complexity in library synthesis - the absolute chiral integrity of all chiral centres in the target molecules. Under certain circumstances the C terminal amino acid of an assembled sequence can undergo epimerisation with the resulting loss of chiral integrity.
- Solid phase based syntheses utilise a cross-linked polymer (a resin support) which is functionalised with a chemically reactive unit (a linker).
- a functional group (carboxylic acid, amine, hydroxyl, sulphydryl etc) from an initial intermediate of the final desired compound is reversibly and covalently attached to the resin through the linker.
- Sequential chemical transformations of this now resin-bound intermediate to the final compound are then performed.
- excess and spent reagents are removed from the growing resin-bound product by simple filtration and washing - this being the overriding factor providing expedient synthesis compared to solution based synthesis.
- the fully assembled product is released from the solid support by cleavage of the covalent bond between the linker and product functional group.
- peptidyl acyloxymethyl ketones a potent class of inhibitor of the cysteinyl protease Derp I, a major allergen of the house dust mite contain no obvious functional group by which a linker can attach an intermediate to a resin. Therefore current solid phase techniques cannot prepare many types of potential drug candidates as single discrete compounds let alone defined libraries of analogues.
- the only functional element that is always required to be present in the target molecule is a single secondary amide group.
- the attachment of initial intermediates through the conserved secondary amide group to a resin support provides a unique route to any class of linear compounds.
- the covalent bond between the linker and now tertiary amide is cleaved to regenerate the conserved secondary amide.
- Coupling reactions the addition of a new chemical moiety providing a part of the final product
- each coupling stage may be performed using chemical mixtures, providing a combinatorial library of final products in which both the N and C terminal residues have been varied. This latter route greatly expands the number and range of drug-like molecules that may be accessed in an overall drug discovery programme.
- backbone amide protecting groups which generate amides upon acidolytic treatment described in the literature.
- Johnson, Quibell and Sheppard have described the development of a backbone amide protection system.
- This system (not a linker in its own right) was designed to protect the backbone amide of a peptide (previously attached to the resin through a C-terminal residue- linker moiety) during synthesis.
- the group was removed as a final step along with side-chain deprotection and peptide- linker cleavage by trifluoroacetic acid (TFA).
- TFA trifluoroacetic acid
- this linker has the limitation that under certain circumstances a C ⁇ terminal amino acid can undergo epimerisation with the resulting loss of chiral integrity.
- loss of chiral integrity may occur.
- An example of this is the preparation of backbone cyclised peptides.
- the C-terminal amino acid residue of a peptide sequence is activated, without urethane protection, facilitating closure to a cyclic peptide and may give significant epimersiation of the C ⁇ of the activated amino acid residue.
- This problem severely restricts the fully flexible synthesis of cyclic peptides. with full chiral integrity, to a method of preparation which relies on the activation of a glycine (achiral), or proline (good chiral stability) respectively.
- the present invention provides the means to suppress epimerisation of the C ⁇ terminal amino acid of a protected peptide sequence during coupling by using the protection moiety shown in (1) which is referred to as a "'precursor linker * ' by virtue of having the aldehyde group.
- This moiety has a number of features; the functional group R and the 2- hydroxyl function lie in a para position relative to each other while the ether residue lies in a para position relative to the aldehyde residue.
- Rl is an electron donating alkyl group.
- the R group is a moiety that may readily be interconverted between electron- withdrawing and electron donating. This is based on the safety catch principle. The principle, that a stable bond is smoothly converted to a labile one at a convenient point during a synthesis, has been applied in peptide chemistry for the development of linkers and protecting groups. One approach has been to exploit the facile reductive conversion of a sulphoxide to sulphide. This approach when applied to the precursor linker (1) provides the functional protection moieties which are referred to as "linker compounds".
- the present invention provides a resin linked compound of the general formula:
- X is (CH 2 ) n R3 where R3 is an -CO- group for attachment to the terminal NH group of the solid phase through a standard bond eg carboxyl amide;
- Rl is methyl or another such suitable alkyl known in the art; n is between 2 and 12, preferably 4;
- Y is H or an N ⁇ functional group protective moiety such as Fmoc;
- R2 is a variable residue
- R2 1 is an intermediate form of R2 which is subsequently chemically transformed to give the desired R2.
- the present invention provides an alternative presentation of the linker whereby the attachment to the solid phase via X is through the ether residue of (B), as shown in (C).
- X is (CH 2 ) ⁇ R3, where R3 is an -CO- group for attachment to the terminal NH group of the solid phase through a standard bond eg carboxyl amide;
- Rl is methyl or another such suitable alkyl known in the art; and n is between 2 and 12, preferably 4.
- the invention provides a methodology for producing the compounds above as well as providing for the compounds which are the products of the said methods.
- X is (CH 2 ) n R3
- (CH 2 ) is selected from: (a) a linear alkyl group; (b) a branched alkyl group; and (c) a non-aromatic ring system which may optionally be attached to a linear or branched alkyl group.
- Analytical HPLC was performed using a Phenomenex Jupiter C4 reversed phase column (250 x 4.6 mm id). Solvent system used: solvent A: 0.1% aqueous TFA. Solvent B: 90% acetonitrile, 10% solvent A. Analytical gradient used 10% solvent B, to 90% solvent B over 27 min. Mass spectra were recorded using a Fisons VG single platform spectrometer in either positive ES (electrospray) or APCI (Atmospheric Pressure Chemical Ionisation) mode. 400MHz NMR were acquired at the University of Cambridge NMR service. Chemical shifts are reported in parts per million and were referenced to residual solvent peaks within deuterated solvents.
- DEPT disortionless enhancement through polarization transfer
- (0); CH or CH 3 (positive) and (1); C or CH; (negative) signals (0); CH or CH 3 (positive) and (1); C or CH; (negative) signals.
- Analytical thin-layer chromatography (TLC) was conducted on prelayered silica gel Plates. Visualisaxion of plates was accomplished using a 254 nm UV light (for chromophores). Flash chromatography was conducted upon Kieselgel 60, 230-400 mesh and was run under a slight positive pressure.
- Solvents used were either reagent or HPLC grade. Reactions were carried out at ambient temperature under nitrogen unless otherwise noted. Solvent mixtures are expressed as volume: volume ratios. All starting materials were commercially available unless otherwise stated.
- Resorcinol 0.1 mmol, 11s
- copper sulphate 0.2mmol, 3 l.Sg
- Ammonium thiocyanate 0.4mmol, 31g
- the resultant white suspension was filtered through celite; and washed with a further 50mL of water.
- the resultant filtrate was stirred vigorously with the addition of sodium carbonate (0.5mmol, 5.3g) in water (50mL) in one portion.
- 6-(tert-butoxy)-2H-l,3-benzoxathiol-2- ⁇ ne (2) (l lmmol, 2.49g) was dissolved in dioxane (105mmol, 9.60mL) with vigorous stirring at 5°C. A 2N solution of NaOH (10.56mL) was added in a dropwise manor over 10 minutes with vigorous stirring. Cooling was maintained for 10 minutes further then the solution was allowed to warm to room temperature for 1 hour. Dioxane was removed in vacuo, the remaining slurry was taken up in water (lOmL) and washed with tert-butyl ether (20mL).
- the resultant resin-handle complex was washed with DMF (5 x 2 min), CH2CI2 (5 x 2 min), MeOH (3 x 2 min) and TBDME ( 5 2 min).
- the resin was dried imtially under a positive nitrogen pressure and then in vacuo.
- Linker-resin complex (10) was allowed to eqilibrate in trimethylorthoformate (15mL) containing H-L-Leu-CTMA (28mmol, 4.62g). The reaction is allowed to proceed in a capped syringe for 5 hours. The resultant resin-complex was washed with dry THF (5 x 2 min) and dried under a positive pressure of nitrogen. The resin was then suspended in dry THF/ acetic acid/water (90:5:5, v/v/v, 20mL) containing sodium cyanoborohydride (14mmol, 882mg) for 14 hours.
- the resultant resin conjugate was washed with DMF/water (9:1, v/v, 20mL x 9), MeOH (20mL x 9) and tert-butyl ether (30mL x 1) allowing the solvent to percolate through the resin bed for 30 seconds.
- the resin conjugate was dried under a positive nitrogen pressure and in vacuo for 2 hours.
- the resin-linker-AA-OCTMA complex was initially reated with Fmoc-Cl and DIEA to protect the the secondary amine mtrogen prior to oxidation of the sulfide.
- the nitrogen dried resin conjugate (500mg) was suspended in a solution of MCPBA (250mg in 25mL DCM). The reaction was allowed to proceed in a capped syringe for 5 hours.
- the resultant resin-complex was washed with DCM (2 x 20mL), DMF (2 x 20mL), methanol (2 x 20mL) and finally tert-butyl ether (2 x 20mL).
- the resin conjugate was dried under a positive nitrogen pressure and finally in a vacuum desicator overnight. Acylation of resin conjugate (11) via symmetrical anhydrides. (A general case)
- Fmoc-amino acid (20eq excess to resin loading) is dissolved / suspended in dichloromethane (5mL / mmol amino acid) with stirring and ice cooling in a 50mL Falcon tube. If the amino acid appears insoluble , then DMF (500 ⁇ L) is added to aid dissolution. Diisopropylcarbodiimide(l ⁇ eq) in DCM (lmL) is added over a few minutes, and the mixture stirred at 0°C for 30 minutes. Resin conjugate (11) was added to the anhydride solution, sealed and left to react for the appropriate time. The fully acylated resin cojugate is filtered and washed with DMF (5 x 50mL), methanol (5 x 50mL) and tert-butyl ether (2 x 50mL).
- Solid phase peptide chemistry was carried out using standard solid phase Fmoc-AA-Opfp / HOBt couplings.
- the C-terminal protecting group chosen was the in house developed Fmoc-AA-OCTMA derivatives. These Fmoc amino acid derivatives are stable throughout Fmoc-polyamide peptide synthesis, and can be removed using weak solutions of TFA in conjunction with the appropriate scavengers (TFA / TES).
- Pepti de-resin conjugate (lOOmg) was suspended in a solution of 2%TFA / 1%TES in DCM (lOmL) for 15 minute x 2. The resin was filtered, washed with DMF (5 x lOmL), methanol (5 x lOmL) and tert butyl ether (5 x lOmL) and dried under a positive nitrogen pressure. Cvclization to give cvclo A AAi - AA?- AAi- AA.- AA*- A ⁇ A-
- Peptide-resin 50mg, 0.24mmol / g, was treated with suspended in 1ml of a solution of DMF containing BOP (16mg, 0.036mmol), HOBt (6mg, 0.036mmol) and NMM (4 ⁇ L, 0.036mmol).
- the resin was aggitated for 24 hours, removal of reagents occurred via filtration, followed by washing with DMF (2 x 2mL), methanol (2 x 2mL) and tert-butyl ether (2 x 2mL). The resin was dried under a positive pressure of nitrogen prior to cleavage.
- Peptide-resin 50mg, 0.24mmol / g, was treated with suspended in 1ml of a solution of DMF containing BOP (16mg, 0.036mmol). HOBt (6mg, 0.036mmol) and NMM (4 ⁇ L, 0.036mmol) and H-AA-AMC (0.036mmol). The resin was aggitated for 2 hours, removal of reagents occurred via filtration, followed by washing with DMF (2 x 2mL), methanol (2 x 2mL) and tert-butyl ether (2 x 2mL). The resin was dried under a positive pressure of nitrogen prior to cleavage.
- Peptide-resin conjugate (50mg, 0.24mmol g "1 substitution) was suspended in TFA / TES / DMS / H 2 0 (90/1/1/8) containing 1 mol % of NELL The suspension was aggitated at room temperature for 2 hours. The resin was filtered, the resultant filtrate was sparged down under a stream of nitrogen and the peptide precipitated via the slow addition of cold ten butyl ether, spun down via centrifugation and air dried prior to HPLC analysis.
- Linear peptide sequence prepared via Fmoc polyamide synthesis Compound of general formula cyclo XAAi-TL i-AArAAj-AAs-AAe)- H-Leu-Tyr-Leu-Ser-Gln-Leu-OH, C 35 H 37 N 7 O ⁇ o ; calculated 735.89, found 736.5 (MET). HPLC retention 12.78 minutes.
- Combinatorial libraries of peptidyl cyclic compounds which can be cyclised from linear compounds of general formula (D) and cleaved to provide cyclic compounds of the general formula (E) in which AA r AA 3 are independently combinatorially variable.
- the class of compound (D) can utilise any available residue, be it a peptide, peptidomimetic or other, as during the synthesis the chiral integrity of the C ⁇ is protected. Therefore, the need to include specialised residues in this position, such as proline or glycine, which cannot easily be epimerised in the reaction, is eliminated.
- the present invention can be used to produce combinatorial libraries useful for designing appropriate peptide-based substrates and inhibitors for proteases (and other enzymes).
- a known class of compounds having three variable amino acid residues X of general formula Ac-X-X-X-Asp-aminomethylcoumarin have been proposed for investigating protease specificities of interleukin-l ⁇ converting enzyme (ICE) - ref: Rans et al, Chem. & Biol., 1997, Vol. 4, No. 2.
- ICE interleukin-l ⁇ converting enzyme
- the present invention allows for the production of a general library class of compounds -X-X-X-X-AMC which have four variable amino acid residues X. Such compounds are referred to hereafter as "4X-AMC".
- the compounds can be synthesised according to the present invention and libraries of the compounds can be used to rapidly and accurately assess enzymatic specificity.
- Scheme 5 provides a generic synthetic route to 4X-AMC compoimds
- Scheme 6 provides a specific example of the synthesis of the compound Ac-Tyr-Leu-Leu-Lys- AMC.
- step A the compound prior to step A could be chosen to have tha-SOMe rather than the -SMe substituent.
- the reductive amination of step A would reduce -SOMe to -SMe followed by re-oxidation to -SOMe in step B.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002311490A CA2311490A1 (fr) | 1997-11-26 | 1998-11-26 | Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide |
AU13420/99A AU734992B2 (en) | 1997-11-26 | 1998-11-26 | A solid-phase technology for the preparation of combinatorial libraries through amide-bond anchoring |
EP98956988A EP1034154A1 (fr) | 1997-11-26 | 1998-11-26 | Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide |
JP2000522063A JP2001524457A (ja) | 1997-11-26 | 1998-11-26 | アミド結合固着による混成ライブラリー調製のための固相技術 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9724853.8A GB9724853D0 (en) | 1997-11-26 | 1997-11-26 | A solid-phase technology for the preparation of combinatorial libraries through amide-bond anchoring |
GB9724853.8 | 1997-11-26 | ||
GB9808744.8 | 1998-04-25 | ||
GBGB9808744.8A GB9808744D0 (en) | 1998-04-25 | 1998-04-25 | A solid-phase technology for the preparation of combinatorial libraries through amide-bond anchoring |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999026902A1 true WO1999026902A1 (fr) | 1999-06-03 |
Family
ID=26312654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003523 WO1999026902A1 (fr) | 1997-11-26 | 1998-11-26 | Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1034154A1 (fr) |
JP (1) | JP2001524457A (fr) |
AU (1) | AU734992B2 (fr) |
CA (1) | CA2311490A1 (fr) |
WO (1) | WO1999026902A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1115739A4 (fr) * | 1998-09-25 | 2004-10-27 | Univ Queensland | Auxiliaire pour la formation de liaisons amides |
US7589170B1 (en) | 1998-09-25 | 2009-09-15 | The University Of Queensland | Synthesis of cyclic peptides |
CN117924235A (zh) * | 2024-01-19 | 2024-04-26 | 王叔和生物医药(武汉)有限公司 | 硫氰酸钠在氧化间苯二酚合成制备噻克索酮中的应用及噻克索酮的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018144A1 (fr) * | 1991-04-12 | 1992-10-29 | Michal Lebl | Benzhydrylamines substituees utilisees comme elements d'espacement bifonctionnels de liaison pour la synthese de peptides en phase solide |
WO1996000378A1 (fr) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Compose photolabiles et procedes pour leur utilisation |
WO1998017628A2 (fr) * | 1996-10-22 | 1998-04-30 | Peptide Therapeutics Limited | Technique en phase solide pour la preparation d'amides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2252508A1 (fr) * | 1996-04-24 | 1997-10-30 | Peptide Therapeutics Limited | Substrats et inhibiteurs d'enzymes proteolytiques |
-
1998
- 1998-11-26 WO PCT/GB1998/003523 patent/WO1999026902A1/fr not_active Application Discontinuation
- 1998-11-26 AU AU13420/99A patent/AU734992B2/en not_active Ceased
- 1998-11-26 CA CA002311490A patent/CA2311490A1/fr not_active Abandoned
- 1998-11-26 JP JP2000522063A patent/JP2001524457A/ja active Pending
- 1998-11-26 EP EP98956988A patent/EP1034154A1/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018144A1 (fr) * | 1991-04-12 | 1992-10-29 | Michal Lebl | Benzhydrylamines substituees utilisees comme elements d'espacement bifonctionnels de liaison pour la synthese de peptides en phase solide |
WO1996000378A1 (fr) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Compose photolabiles et procedes pour leur utilisation |
WO1998017628A2 (fr) * | 1996-10-22 | 1998-04-30 | Peptide Therapeutics Limited | Technique en phase solide pour la preparation d'amides |
Non-Patent Citations (1)
Title |
---|
CALMES M ET AL: "USE OF A NEW SONICALLY CLEAVABLE AND ACIDO-LABILE HANDLE FOR SOLID-PHASE PEPTIDE AMIDE SYNTHESIS", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 44, no. 1, 1 July 1994 (1994-07-01), pages 58 - 60, XP000451983 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1115739A4 (fr) * | 1998-09-25 | 2004-10-27 | Univ Queensland | Auxiliaire pour la formation de liaisons amides |
US7589170B1 (en) | 1998-09-25 | 2009-09-15 | The University Of Queensland | Synthesis of cyclic peptides |
US7718598B1 (en) | 1998-09-25 | 2010-05-18 | The University Of Queensland | Auxiliary for amide bond formation |
CN117924235A (zh) * | 2024-01-19 | 2024-04-26 | 王叔和生物医药(武汉)有限公司 | 硫氰酸钠在氧化间苯二酚合成制备噻克索酮中的应用及噻克索酮的制备方法 |
CN117924235B (zh) * | 2024-01-19 | 2024-08-06 | 王叔和生物医药(武汉)有限公司 | 硫氰酸钠在氧化间苯二酚合成制备噻克索酮中的应用及噻克索酮的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU1342099A (en) | 1999-06-15 |
CA2311490A1 (fr) | 1999-06-03 |
EP1034154A1 (fr) | 2000-09-13 |
JP2001524457A (ja) | 2001-12-04 |
AU734992B2 (en) | 2001-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6368874B1 (en) | Methods for hard-tagging an encoded synthetic library | |
FI94254C (fi) | Menetelmä terapeuttisesti aktiivisten peptidijohdannaisten valmistamiseksi | |
US9169295B2 (en) | Macrocycles and macrocycle stabilized peptides | |
WO1996034878A1 (fr) | Synthese de proteines par ligature chimique endogene | |
WO2011098999A2 (fr) | Préparation chimique de thioesters d'ubiquitine et modifications de ces derniers | |
JP2005529166A (ja) | ペプチドカップリングのための試薬の化学合成 | |
Clave et al. | A novel heterotrifunctional peptide-based cross-linking reagent for facile access to bioconjugates. Applications to peptide fluorescent labelling and immobilisation | |
EP1034154A1 (fr) | Technologie en phase solide pour l'elaboration de bibliotheques combinatoires par via ancrage par liaison amide | |
CA2269589C (fr) | Technique en phase solide pour la preparation d'amides | |
JP2888991B2 (ja) | Nα−2−(4−ニトロフェニルスルフォニル)エトキシカルボニル−アミノ酸 | |
US20070059792A1 (en) | Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation | |
Hughes | Amino Acids, Peptides and Proteins in Organic Chemistry, Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis | |
CN100395270C (zh) | 线型聚苯乙烯支载的(4s)-5,5-二取代基噁唑烷酮及其制备方法和用途 | |
EP1100812A2 (fr) | Procede de derivatisation d'une resine et utilisations du produit obtenu | |
US6566520B2 (en) | Support for synthesis and purification of compounds | |
US6359113B1 (en) | Protective group, compound protected by said group and device for grafting the protective group on the compound to protect it | |
JP2002521364A (ja) | アミノ−アルデヒド固相支持体、そのためのリンカー並びにそれを製造する方法およびその用途 | |
CN114901673A (zh) | 溶液相肽核酸寡聚体的制备方法 | |
Dugave | Design of new photoactivatable amino acids: Stereoselective synthesis of N-protected phenylalanine derivatives as precursors of p-diazocyclohexadienone-containing peptides | |
US6190920B1 (en) | Method for detecting enzyme catalyzed cyclization | |
Bochet et al. | Photolabile linker units | |
WO2003093301A2 (fr) | Procede permettant de synthetiser des peptides | |
US6797829B1 (en) | Synthesis of a novel paramagnetic amino derivative (epm-5) for labelling chemical and biological macromolecules | |
Babaev et al. | Basic techniques of working on a solid phase: From ABC of the peptide synthesis to libraries of non-natural amino acids | |
WO2005100378A1 (fr) | Procede pour la preparation d'un peptide, et composes comportant un groupe d'activation de carboxyle thioester pour utilisation dans un tel procede |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998956988 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2311490 Country of ref document: CA Ref country code: CA Ref document number: 2311490 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13420/99 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09554579 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998956988 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 13420/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998956988 Country of ref document: EP |